We are live on ! Find out more
TSV

Two Sigma Ventures Portfolio holdings

AUM $9.61M
1-Year Est. Return 58.41%
This Fund
S&P 500
This Quarter Est. Return
+30.71%
1 Year Est. Return
-58.41%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$9.61M
AUM Growth
-$6.96M
Cap. Flow
-$11M
Cap. Flow %
-114.56%
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$9.15M
2
ZY
Zymergen Inc. Common Stock
ZY
+$1.86M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXRX icon
1
Recursion Pharmaceuticals
RXRX
$1.84B
$9.61M 100%
903,400
-903,400
-50% -$9.15M
ZY
2
DELISTED
Zymergen Inc. Common Stock
ZY
– –
-1,513,727
Closed -$1.86M

Similar funds

CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
AG
AlphaSimPlex Group Boston, Massachusetts $9.88M AUM 8.01% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
PL
Portland Ltd Grand Cayman, Cayman Islands $10.9M AUM 72.34% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
LGI
Lakestar Growth I St. Peter Port, Guernsey $11.5M AUM 71.31% 1-Year Est. Return

Two Sigma Ventures's Q3 2022 Portfolio in Review

As of Q3 2022, Two Sigma Ventures held 2 positions worth $9.61M, down 42% from $16.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Two Sigma Ventures withdrew a net $11M in Q3 2022, closing 1 position and reducing 1 holding. Its most notable exit was Zymergen Inc. Common Stock, an estimated $1.86M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Two Sigma Ventures's biggest Q3 2022 reduction was Recursion Pharmaceuticals, cutting an estimated $9.15M.
  • Two Sigma Ventures fully exited Zymergen Inc. Common Stock in Q3 2022, selling an estimated $1.86M.
  • Two Sigma Ventures's ten largest holdings make up 100% of its $9.61M portfolio in Q3 2022.
  • Two Sigma Ventures opened 0 new positions and closed 1 in Q3 2022.
  • Two Sigma Ventures's portfolio value fell 42% quarter-over-quarter to $9.61M.

Based on Two Sigma Ventures's 13F filing for Q3 2022, filed 14 Nov 2022.